Pay in 4 interest-free payments of $5.81 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
In the real-world metric (all participants), average weight loss was 20.4%
To put that in perspective, the approved GLP-1 drugs achieved less weight loss in longer timeframes: for example, semaglutide (Wegovy) averages about 15% weight loss over ~16 months, and tirzepatide (Zepbound) achieved around 22.5% at 72 weeks in trials
Hydration matters more than you think Adequate water intake supports digestive function and helps soften stool, reducing the constipation component of bloating
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022: Epic Research: Many Patients Maintain Weight Loss a Year After Stopping Semaglutide and Liraglutide (2024):
